• Institution: LOCKSS
LOCKSS

Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

Figure 2
Figure 2

Magnitude of overexpression of IFN-α/β-inducible gene signature in WB of 41 SLE patients in the initial study as measured by the median fold change of the 25 most overexpressed IFN-α/β-inducible genes (IFN-α/β-inducible gene signature score) in individual SLE patients. The horizontal bars represent the median values. Patients whose IFN-α/β-inducible gene signature score was >10 were considered to have high IFN-α/β-inducible gene signatures; those with scores between 4 and 10 were considered to have moderate IFN-α/β-inducible gene signatures, whereas those with scores < 4 were considered to have weak IFN-α/β-inducible gene signatures. IFN = interferon; SLE = systemic lupus erythematosus.

This Article

  1. Hum Genomics Proteomics vol. 1 no. 1